Immunovant, Inc.

IMVT

$39.00

-0.32%

2026-09-04 09:51:20 EDT-$0.12

Healthcare

Biotechnology

NASDAQ

Active Trading

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of ...

Financial Highlights of IMVT

Profitability trend

Latest / TTM · 6 periods

Gross Margin

97.1%

Net Margin

-7585.9%

P/E Ratio

-13.87x

n/a

Debt / Equity

0.00

n/a

Current Ratio

7.27

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

97.1%

Net Margin

-7585.9%

P/E Ratio

-13.87x

Debt / Equity

0.00

Profitability

Profitability table

Metric	2022	2023	2024	2025	2026	2026
Gross MarginGross profit as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
Operating MarginOperating income as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
Net MarginNet income as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
EBITDA MarginEBITDA divided by revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2022	2023	2024	2025	2026	2026
Current RatioCurrent assets divided by current liabilities.	11.52	9.34	13.70	11.16	9.09	—
Quick RatioLiquid assets divided by current liabilities.	11.52	9.34	13.70	11.16	9.09	—
Cash RatioCash and equivalents divided by current liabilities.	11.09	8.70	13.07	10.38	8.64	—
Debt / AssetsDebt as a share of total assets.	0.5%	0.3%	0.0%	0.0%	0.0%	—
Debt / EquityDebt compared with shareholder equity.	0.01	0.00	0.00	0.00	0.00	—

Operating efficiency

Operating efficiency table

Metric	2022	2023	2024	2025	2026	2026
Receivables TurnoverHow often receivables are collected in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	0.00x	0.00x	0.00x	0.05x	—
Asset TurnoverRevenue generated per dollar of assets.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.00x	0.00x	0.00x	0.00x	0.00x	—

Valuation ratios

Valuation ratios table

Metric	2022	2023	2024	2025	2026	2026
P/E RatioPrice paid for each dollar of earnings.	-3.85x	-9.07x	-16.81x	-6.26x	-8.97x	—
P/B RatioPrice paid for each dollar of book value.	1.29x	5.27x	7.07x	3.66x	5.31x	—
P/S RatioPrice paid for each dollar of sales.	0.00x	0.00x	0.00x	0.00x	0.00x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-5.68x	-10.13x	-20.34x	-6.88x	-11.12x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer